Is Kesimpta Approved for Children?
No, Kesimpta (ofatumumab) is not approved for use in children or adolescents under 18 years old. The FDA approved it solely for adults with relapsing forms of multiple sclerosis (MS), based on trials limited to patients aged 18-55.[1][2]
Why No Pediatric Approval?
Clinical trials for Kesimpta excluded kids due to MS rarity in those under 18—only about 8,000-10,000 U.S. cases—and lack of pediatric-specific data. No studies have established safety, dosing, or efficacy in this group. Novartis, the manufacturer, has not sought pediatric approval.[1][3]
What Happens If Given to Kids Anyway?
Off-label use in children is not recommended and carries unknown risks. Potential issues mirror adult side effects like infusion reactions, infections (e.g., upper respiratory), headache, and injection-site reactions, but kids may face higher vulnerability due to developing immune systems. Long-term effects on growth or immunity remain unstudied.[2][4]
Alternatives for Pediatric MS
Standard treatments for kids with MS include interferon beta-1a (Avonex, Rebif), glatiramer acetate (Copaxone), fingolimod (Gilenya, approved for ages 10+), and siponimod (Mayzent, ages 10+). These have pediatric data from trials showing similar efficacy to adults with manageable safety profiles.[3][5]
Ongoing Research or Future Approval?
No active pediatric trials for Kesimpta appear on ClinicalTrials.gov. Novartis focuses on adult expansions, like combination therapies. Pediatric MS guidelines from the International Pediatric MS Study Group prioritize established options over untested B-cell depleters like Kesimpta.[4][6]
[1]: FDA Label for Kesimpta
[2]: Novartis Kesimpta Prescribing Information
[3]: National MS Society - Pediatric MS Treatments
[4]: ClinicalTrials.gov Search for Ofatumumab Pediatrics
[5]: FDA Approval for Gilenya in Pediatrics
[6]: International Pediatric MS Study Group Guidelines